Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 03:40PM GMT
Release Date Price: $35.07 (-7.49%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

It's the second day of the Bank of America Healthcare Conference. I am Tazeen Ahmad. I'm one of the senior biotech analysts here. It is my pleasure to have sitting with me on stage couple of members from the Apellis Pharmaceuticals management team. I will let Cedric and Tim and Adam introduce themselves to you first. And then Cedric, if you don't mind, give us a quick 2-minute overview of the company. And then we can go into Q&A if that's okay.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Sure. Thank you Tazeen. Thank you for inviting us. My name is Cedric Francois, CEO.

Adam J. Townsend
Apellis Pharmaceuticals, Inc. - Chief Commercial Officer

Hi everyone. Adam Townsend, Chief Commercial officer.

Timothy E. Sullivan;
Apellis Pharmaceuticals, Inc. - CFO & Treasurer

Hi, Tim Sullivan, Chief Financial Officer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot